The UK government has over the weekend pledged further support to the Global Fund to fight AIDS, Tuberculosis and Malaria to help save millions of lives around the world.
Since 2002, The Global Fund has helped save more than 27 million lives and reduced deaths from these three killer infectious diseases by more than a third in the countries which it invests in.
The UK’s new three-year funding pledge will help: provide life-saving antiretroviral therapy to more than 3.3 million people with HIV;provide TB treatment and care for 2.3 million people
The funding will also provide 120,000 people with treatment for multidrug-resistant TB;distribute 92 million mosquito nets to protect children and families from malaria; and strengthen health systems and promote global health security.
International Development Secretary, Rory Stewart said: “We’re deeply proud of our efforts with the Global Fund to fight AIDS, Tuberculosis and Malaria, but far too many people still die from these diseases.“We’re going to continue to invest in controlling and ultimately ending these diseases, and we will be making sure other countries contribute generously.
“These diseases cross borders. Therefore, our support is something that helps the poorest people in the world, but is also something that keeps us safe here at home.”
British expertise is at the heart of global efforts to tackle AIDS, TB and malaria.
The new pledge will average £467 million a year.
On 28th June 2019 Rory Stewart visited ViiV Healthcare in Hertfordshire – a UK business at the heart of tackling one of these diseases.
ViiV Healthcare has developed a new antiretroviral drug to treat HIV and is voluntarily licencing it. This means the Global Fund can negotiate lower prices and supply the drug in large volumes to developing countries, improving the lives of children and adults living with HIV.
April this year, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Dovato, a complete, once-daily, single-tablet regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either DTG or 3TC. Dovato, a two-drug regimen (2DR), reduces exposure to the number of ARVs from the start of treatment, while still maintaining the efficacy and high barrier to resistance of a traditional DTG-based three-drug regimen.
The UK’s investment is crucial as AIDS, tuberculosis and malaria continue to blight the lives of people and communities around the world:
Through the new pledge, the UK government will encourage stronger private sector engagement in the fight against malaria by doubling the value of up to £100 million of investment from private sector organisations.
Executive Director of the Global Fund, Peter Sands, said: The UK’s ongoing effort on global health will promote development and ensure we achieve Global Goal Three: good health and well-being for all people by 2030.